Vanessa Carle PhD
Principal
Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination.
Founded in 2021, Gate Bioscience is creating a new class of small molecule therapeutics: Molecular Gates. The company is led and advised by a team of world-class drug developers and entrepreneurs, and is backed by leading venture investors.
Year Invested
2025
Status
Current
Location
USA
Molecular gates have the potential to be transformative drugs for diseases where current treatments fall short. Because the mechanism is so differentiated, we’ve been able to build a portfolio with low biology risk and best-in-class potential across multiple therapeutic areas.Jordi Mata-Fink, Ph.D.
Co-Founder & CEO
